USA flag logo/image

An Official Website of the United States Government

THE OBJECTIVE OF THIS PROJECT IS TO DEVELOP TECHNIQUES FOR USING MONOCLONAL…

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
4736
Program Year/Program:
1986 / SBIR
Agency Tracking Number:
4736
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Cytogen Corpon
201 College Road East Princeton Forrestal Center Princeton, NJ 08540
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: THE OBJECTIVE OF THIS PROJECT IS TO DEVELOP TECHNIQUES FOR USING MONOCLONAL ANTIBODIES LABELED WITH 212BISMUTH, AN ALPHA PARTICLE-EMITTING RADIONUCLIDE, AS IN VITRO OT IN VIVOCYTOTOXIC AGENTS.
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE OBJECTIVE OF THIS PROJECT IS TO DEVELOP TECHNIQUES FOR USING MONOCLONAL ANTIBODIES LABELED WITH 212BISMUTH, AN ALPHA PARTICLE-EMITTING RADIONUCLIDE, AS IN VITRO OT IN VIVOCYTOTOXIC AGENTS. ANTIBODY CONJUGATES WILL BE DEVELOPED FORRADIOIMAGING TO LOCALIZE TO THE TUMOR SITE ONLY, WITH MINIMAL UPTAKE BY THE RETICULOENDOTHELIAL SYSTEM, MAKING THEM IDEAL AGENTS FOR IMMUNOTHERAPY. THIS SITE-SPECIFIC COVALENT ATTACHMENT OF CHELATORS TO THE OLIGOSACCHARIDES IN THE CONSTANT REGION, AWAY FROM THE ANTIBODY'S BINDING SITE, YIELDS HOMOGENEOUS CONJUGATES THAT RETAIN THEIR ANTIGEN BINDING ACTIVITY AND AFFINITY. THESE CHEMICAL TECHNIQUES ARE AN IMPROVEMENT OVER EXISTING METHODS FOR ANTIBODY MODIFICATION. 212BISMUTH HAS BEEN CHELATED BY DTPA COVALENTLY ATTACHED TO MONOCLONAL ANTITUMOR ANTIBODIES BY THE ABOVE METHODS. IN THIS PHASE I PROJECT, THE RESEARCH WILL DEMONSTRATE IMMUNOSPECIFIC KILLING OF TUMOR CELLS IN VITRO AND STABILITY OF THE MAB-DTPA-212BI CONJUGATE IN VIVO.IN PHASE II, RADIOIMMUNOTHERAPY MAY BE ACHIEVED IN AN IN VIVO MURINE TUMOR MODEL. ANTIBODY LOCALIZATION WILL BE STUDIED AND THERAPEUTIC EFFECTS ASSESSED. THE ULTIMATE GOALOF RADIOIMMUNOTHERAPY IS THE TREATMENT OF HUMANS FOR CANCER.

Principal Investigator:

A dwight lopes
PRINCIPAL INVESTIGATOR
6094528838

Business Contact:

Small Business Information at Submission:

Cytogen Corpon
201 College Road East Princeton Forrestal Center Princeton, NJ 08540

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No